Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tyco Takes Steps To Add InnerDyne Surgical Access Line Via $180 Mil. Bid

This article was originally published in The Gray Sheet

Executive Summary

Tyco International's purchase of InnerDyne for $180 mil. would give the company access to the Sunnyvale, Calif. firm's Step line of minimally invasive access products for laparoscopic surgery.

You may also be interested in...



Cohesion Technologies

William Mavity is named president and CEO, effective Oct. 1. Mavity, 51, formerly served as president and CEO of InnerDyne, which was acquired by Tyco's U.S. Surgical business a year ago (1"The Gray Sheet" Oct. 9, 2000, p. 14). The exec will take over from outgoing David Foster, CEO, and Frank DeLustro, president and chief operating officer, as part of a planned transition to focus on biosurgical product commercialization efforts with "a more seasoned executive," the firm explains. Palo Alto, California-based Cohesion is awaiting a rescheduling of an FDA panel review of its CoSeal surgical sealant following a Sept. 11 cancellation (2"The Gray Sheet" Sept. 17, 2001, p. 7)

Cohesion Technologies

William Mavity is named president and CEO, effective Oct. 1. Mavity, 51, formerly served as president and CEO of InnerDyne, which was acquired by Tyco's U.S. Surgical business a year ago (1"The Gray Sheet" Oct. 9, 2000, p. 14). The exec will take over from outgoing David Foster, CEO, and Frank DeLustro, president and chief operating officer, as part of a planned transition to focus on biosurgical product commercialization efforts with "a more seasoned executive," the firm explains. Palo Alto, California-based Cohesion is awaiting a rescheduling of an FDA panel review of its CoSeal surgical sealant following a Sept. 11 cancellation (2"The Gray Sheet" Sept. 17, 2001, p. 7)

MDMA To Seek Role In Premier "Breakthrough" Device Process At Meeting

Premier's "breakthrough technology" program is likely to be among the issues discussed at an Oct. 18 meeting between the Medical Device Manufacturers Association and the group purchasing organization in Chicago.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel